Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA?

Vera Therapeutics (VERA) drew investor attention after receiving accelerated FDA approval for TRUTAKNA for adult patients with primary IgA nephropathy at risk of disease progression, alongside releasing its latest quarterly financial results.

See our latest analysis for Vera Therapeutics.

Despite the recent regulatory progress, Vera Therapeutics’ share price has been under pressure, with a 30 day share price return down 27.88% and a year to date share price return down 37.70%. At the same time, the 1 year total shareholder return stands at 43.28% and the 3 year total shareholder return at 71.23%, suggesting that earlier momentum is being reassessed as investors weigh the accelerated approval against ongoing losses.

If you want to see how other healthcare names are reacting to similar themes in treatment and regulation, it is worth scanning 43 healthcare AI stocks.

Bulls point to Vera Therapeutics’ first approved product and strong long term shareholder returns. Bears highlight the ongoing losses and recent share price pullback. Which story is more closely aligned with the current valuation reality for this stock?

Preferred Price to Book of 5.4x: Is It Justified?

Vera Therapeutics currently trades on a P/B ratio of 5.4x, which sits below the 8.6x average of its closest peers but above the broader US biotechs industry average of 2.5x. With a last close of $30.29, investors are effectively paying a higher price relative to book value than the sector overall, while still at a discount to a narrower peer group.

P/B compares the company’s market value to its net assets on the balance sheet. For a clinical stage biotech like Vera Therapeutics that is still loss making, traditional earnings based metrics such as P/E are not yet meaningful. Investors often look at P/B alongside pipeline prospects and capital needs. A higher P/B can reflect expectations that future assets and potential cash flows will justify paying more than today’s accounting book value.

According to the SWS DCF model, Vera Therapeutics is trading at $30.29 compared with an estimated future cash flow value of $549.81, which implies a very large discount to that model based fair value. That gap suggests the market is currently far more cautious than the DCF inputs. Vera Therapeutics is forecast to grow revenue at 57.6% per year and is expected to become profitable within three years.

Compared with peers on a P/B basis, Vera Therapeutics screens as relatively inexpensive versus the 8.6x peer average, yet expensive compared with the wider US biotechs industry at 2.5x. The peer discount hints that some investors may be questioning how quickly the current pipeline and forecast growth will translate into returns on equity, given the company is still unprofitable and has a negative return on equity.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 5.4x (ABOUT RIGHT)

However, Vera Therapeutics still carries key risks, as it is loss making with net income of $401.895 million in the red and no reported revenue yet.

Find out about the key risks to this Vera Therapeutics narrative.

Another View on Vera Therapeutics’ Value

The SWS DCF model paints a very different picture for Vera Therapeutics. At a share price of $30.29 and an estimated future cash flow value of $549.81, the stock screens as very heavily undervalued under this approach. That is a wide gap for investors to interpret. Is the model too optimistic, or is the market being too cautious?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Vera Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With both risks and rewards in play for Vera Therapeutics, sentiment in this article is mixed. Consider reviewing the details promptly for yourself, then weigh the 2 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond Vera Therapeutics?

If Vera Therapeutics has you thinking harder about risk and reward, do not stop here. Use targeted stock ideas to sharpen your next investment decision.

• Target steady compounding potential by reviewing companies screened for reliable income using the 8 dividend fortresses.
• Hunt for opportunities that combine quality with attractive pricing by scanning the 49 high quality undervalued stocks.
• Spot opportunities others may be overlooking by working through the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com